The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

By B. Pitt, F. Zannad, W. Remme, R. Cody, A. Castaigne, Alfonso T. Perez, J. Palensky, J. Wittes. 2000

5,262 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/bac638d3d7859fe294cb8c51d791a68f7273e6df

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. G. Fonarow
2. J. Cleland
3. C. Yancy
4. Gerasimos Filippatos
5. Birgit Funke
6. Xiaobo Mao
7. Gui-wen Yi
8. L. Tavazzi

Citations in the corpus

• Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. (2005, background): “Aldosterone antagonists are recommended in addition to ACE-inhibitors, beta-blockers and diuretics in advanced heart failure (NYHA III–IV) with systolic dysfunction to improve survival and morbidity (Class of recommendation I, level of evidence B).(62)”
• Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician (2018, background): “An example of this can be seen in RCT versus real-world data for mortality in patients with severe heart failure treated with the aldosterone inhibitor spironolactone [56].”
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡ (2008, neutral): “† A single large RCT (RALES) has been undertaken with the aldosterone antagonist spironolactone in patients with severe HF.(108) † In RALES 1663 patients with an LVEF 35% and in NYHA functional class III (having been in class IV within the past 6 months) were randomized to placebo or spironolactone ”
• 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the preventionof sudden cardiac death (2015, positive): “MRAs reduce mortality and reduce rates of sudden death in patients with HF who are already receiving ACE inhibitors and betablocker therapy.(143,308,309) In the most recent trial involving eplerenone, 20% of patients also had an implanted device (ICD or CRT), but the drug was equally effective in pa”
• 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. (2017, methodology): “I ACE-I: A The clinical strategy of inhibition of the reninangiotensin system with ACE inhibitors (Level of Evidence: A) (128-133), OR ARBs (Level of Evidence: A) (134-137), OR ARNI (Level of Evidence: B-R) (138) in conjunction with evidencebased beta blockers (9, 139, 140), and aldosterone antagoni”
• Task Force on Sudden Cardiac Death of the European Society of Cardiology. (2001, background): “Beta-blockers Class I A [74,186,193,197,199,202,203,203] ACE inhibitors Class I A [116,117,128,133–136] Aldosterone receptor blockers Class I B [119] Positive inotropic agents phosphodiesterase inhibitors Class III B [177] Digoxin Class III B [178]”
• Dilated Cardiomyopathy (2007, positive): “ACEi [29, 32, 33], ARB [34, 35], beta-blocker [36–38], and MRA [39, 40] have demonstrated, in several clinical trials, to reduce risk of HF hospitalization and death in patient with HF and reduced EF.”